Immunotherapy drug currently approved by the U.S. Food and Drug Administration (FDA) to treat several forms of cancer is also effective for treating aggressive variants of endometrial cancer, as per the results from phase II clinical trial.
Researchers enrolled 90 women diagnosed with recurrent or advanced endometrial cancer to determine whether the drug pembrolizumab (marketed as Keytruda) could be used to effectively treat this subset of patients with MMR deficiency (dMMR) or MSI-high tumors....
Immunotherapy drug currently approved by the U.S. Food and Drug Administration (FDA) to treat several forms of cancer is also effective for treating aggressive variants of endometrial cancer, as per the results from phase II clinical trial.
Researchers enrolled 90 women diagnosed with recurrent or advanced endometrial cancer to determine whether the drug pembrolizumab (marketed as Keytruda) could be used to effectively treat this subset of patients with MMR deficiency (dMMR) or MSI-high tumors....